THE ENIGMA OF HLA-MEDIATED ADVERSE DRUG REACTIONS: EPOXIDE BUT NOT CARBAMAZEPINE INDUCES THE BINDING OF HAPTENATED PEPTIDES TO HLA-B*15:02

被引：0
|
作者：
Simper, Gwendolin S. [1 ]
Celik, Alexander A. [1 ]
Ho, Gia-Gia T. [1 ]
Huyton, Trevor [2 ]
Kuhn, Joachim [3 ]
Blasczyk, Rainer [1 ]
Bade-Doeding, Christina [1 ]
机构：
[1] Hannover Med Sch, Hannover, Germany
[2] Max Planck Inst, Gottingen, Germany
[3] Heart & Diabet Ctr North Rhine Westphalia, Bad Oeynhausen, Germany
来源：
HLA | 2018年 / 91卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
O1
引用
收藏
页码：322 / 322
页数：1
相关论文
共 50 条
  • [1] Carbamazepine-Mediated Adverse Drug Reactions: CBZ-10,11-epoxide but Not Carbamazepine Induces the Alteration of Peptides Presented by HLA-B*15:02
    Simper, Gwendolin S.
    Ho, Gia-Gia T.
    Celik, Alexander A.
    Huyton, Trevor
    Kuhn, Joachim
    Kunze-Schumacher, Heike
    Blasczyk, Rainer
    Bade-Doeding, Christina
    JOURNAL OF IMMUNOLOGY RESEARCH, 2018, 2018
  • [2] HLA-B*15:11 status and carbamazepine-induced severe cutaneous adverse drug reactions in HLA-B*15:02 negative Chinese
    Wong, Christina S. M.
    Yap, Desmond Y. H.
    Ip, Patrick
    Wong, Wilfred H. S.
    Chua, Gilbert T.
    Yeung, Chi-Keung
    Chan, Henry H. L.
    Kwok, Janette S. Y.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2022, 61 (02) : 184 - 190
  • [3] Update on HLA-B*15:02 allele associated with adverse drug reactions
    Zhu, Xueting
    Luo, Guanghua
    Zheng, Lu
    PHARMACOGENOMICS, 2024, 25 (02) : 97 - 111
  • [4] Association between HLA-B*15:02 and carbamazepine induced severe cutaneous adverse drug reactions in Myanmar
    Khor, Amy Hui-Ping
    Aye, Seinn Mya Mya
    Lim, Kheng-Seang
    Aung, Yan Lynn
    Aye, Yin Minn
    Ohnmar
    Thit, Win Min
    Tan, Chong-Tin
    Ng, Ching-Ching
    NEUROLOGY ASIA, 2017, 22 (03) : 283 - 285
  • [5] Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand
    Rattanavipapong, Waranya
    Koopitakkajorn, Tanunya
    Praditsitthikorn, Naiyana
    Mahasirimongkol, Surakameth
    Teerawattananon, Yot
    EPILEPSIA, 2013, 54 (09) : 1628 - 1638
  • [6] Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population
    C-C Chang
    C-C Ng
    C-L Too
    S-E Choon
    C-K Lee
    W-H Chung
    S H Hussein
    K-S Lim
    S Murad
    The Pharmacogenomics Journal, 2017, 17 : 170 - 173
  • [7] Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population
    Chang, C-C
    Ng, C-C
    Too, C-L
    Choon, S-E
    Lees, C-K
    Chung, W-H
    Hussein, S. H.
    Lim, K-S
    Murad, S.
    PHARMACOGENOMICS JOURNAL, 2017, 17 (02): : 170 - 173
  • [8] Implementation of HLA-B*15:02 Genotyping as Standard-of-Care for Reducing Carbamazepine/Oxcarbazepine Induced Cutaneous Adverse Drug Reactions in Thailand
    Tiwattanon, Kanyawan
    John, Shobana
    Koomdee, Napatrupron
    Jinda, Pimonpan
    Rachanakul, Jiratha
    Jantararoungtong, Thawinee
    Nuntharadthanaphong, Nutthan
    Kloypan, Chiraphat
    Biswas, Mohitosh
    Boongird, Apisit
    Sukasem, Chonlaphat
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [9] Proteome analysis of drug susceptible HLA-B*57:01+ cells reveals the pivotal mechanisms of HLA-mediated carbamazepine hypersensitivity
    Haukamp, Funmilola Josephine
    Hartmann, Zoe Maria
    Pich, Andreas
    Kuhn, Joachim
    Blasczyk, Rainer
    Stieglitz, Florian
    Bade-Doeding, Christina
    HLA, 2023, 101 (04) : 329 - 330
  • [10] HLA-A*31:01 and HLA-B*15:02 as Genetic Markers for Carbamazepine Hypersensitivity in Children
    Amstutz, U.
    Ross, C. J. D.
    Castro-Pastrana, L. I.
    Rieder, M. J.
    Shear, N. H.
    Hayden, M. R.
    Carleton, B. C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (01) : 142 - 149
12345